dentification of Benzoxazolinone Derivatives Based Inhibitors for Depression and Pain Related Disorders Using Human Serotonin and Norepinephrine Transporter as Dual Therapeutic Target: A Computational Approach
Keywords:
2-Benzoxazolinone, Serotonin transporter, Norepinephrine transporter, Acanthus ilicifolius, Genetic Optimization for Ligand Docking, hNET/hSERTAbstract
Pain is commonly associated with depression. Both pain and depression share common biological pathways and neurotransmitters, which has implications for the treatment of both disorders. A drug that could ameliorate both pain and depression could be beneficial in the development of new therapeutics in the management of disorders associated with pain/depression dyad. Alterations in the neurotransmitters namely, serotonin and norepinephrine in the central nervous system (CNS) have been implicated in the pathophysiology of pain and depression. Serotonin and norepinephrine reuptake inhibitors (SNRIs) have been implicated as a novel therapeutic target for a wide range of biological functions, including pain, anxiety and depression. 2-benzoxazolinone (2-BOA) from the mangrove Acanthus ilicifolius and its derivatives have been reported for its analgesic and antidepressant activities. In the present work, docking studies were done on the crystal structure of human transporters of serotonin (hSERT) and on homology modeled human transporters of norepinephrine (hNET) as therapeutic targets of depression and pain related disorders using 2-BOA and its derivatives as potential candidates. A homology model for hNET was constructed using MODELLER and validated. Further docking studies were done on hSERT and hNET using 2-BOA and its structural analogs. The result of the study proposes the possible potential candidate among 2-BOA derivatives that may be further developed as a therapeutic lead compound for use in disorders associated with depression and pain.
References
. Hanna MM, Eid NM, George RF and
Safwat HM. Synthesis of some tropane
derivatives of anticipated activity on the
reuptake of norepinephrine and/or
serotonin. Bioorg Med Chem. 2007;
(24): 7765-7772.
. Andersen J, Stuhr-Hansen N,
Zachariassen L, Toubro S, Hansen SM,
Eildal JN, Bond AD, Bogeso KP, BangAndersen B, Kristensen AS and
Stromgaard K. Molecular determinants
for selective recognition of
antidepressants in the human serotonin
and norepinephrine transporters. Proc
Natl Acad Sci U S A. 2011; 108(29):
-12142.
. Vickers T, Dyck B, Tamiya J, Zhang M,
Jovic F, Grey J, Fleck BA, Aparicio A,
Johns M, Jin L, Tang H, Foster AC and
Chen C. Studies on a series of
milnacipran analogs containing a
heteroaromatic group as potent
norepinephrine and serotonin
transporter inhibitors. Bioorg Med Chem
Lett. 2008; 18 (11): 3230-3235.
. Nencetti S, Mazzoni MR, Ortore G,
Lapucci A, Giuntini J, Orlandini E, Banti
I, Nuti E, Lucacchini A, Giannaccini G
and Rossello A. Synthesis, molecular
docking and binding studies of selective
serotonin transporter inhibitors. Eur J
Med Chem. 2011; 46(3): 825-834.
. Kharkar PS, Reith ME and Dutta AK.
Three-dimensional quantitative
structure-activity relationship (3D QSAR)
and pharmacophore elucidation of
tetrahydropyran derivatives as serotonin
and norepinephrine transporter
inhibitors. J Comput Aided Mol Des.
; 22 (1): 1-17.
. Manepalli S, Geffert LM, Surratt CK and
Madura JD. Discovery of novel selective
serotonin reuptake inhibitors through
development of a protein-based
pharmacophore. J Chem Inf Model.
; 51(9): 2417-2426.
. Hall FS, Schwarzbaum JM, Perona MT,
Templin JS, Caron MG, Lesch KP,
Murphy DL and Uhl GR. A greater role
for the norepinephrine transporter than
the serotonin transporter in murine
nociception. Neuroscience. 2011; 175:
-327.
. Games G and Hutchison A. TapentadolER for the treatment of diabetic
peripheral neuropathy. Consult Pharm.
; 28 (10): 672-675.
. Attal N. Pharmacological treatment of
neuropathic pain in primary care. Rev
Prat. 2013; 63 (6): 795-802.
. Fitzgerald KT and Bronstein AC.
Selective serotonin reuptake inhibitor
exposure. Top Companion Anim Med.
; 28 (1): 13-17.
. Gabrielsen M, Sylte I, Dahl SG and
Ravna AW. A short update on the
structure of drug binding sites on
neurotransmitter transporters. BMC Res
Notes. 2011; 4: 559.
. Whiteside GT, Dwyer JM, Harrison JE,
Beyer CE, Cummons T, Manzino L,
Mark L, Johnston GH, Strassle BW,
Adedoyin A, Lu P, Piesla MJ, Pulicicchio
CM, Erve JC, Platt BJ, Hughes ZA,
Rogers KE, Deecher DC, Trybulski EJ,
Kennedy JD, Zhang P and Leventhal L.
WAY-318068: a novel, potent and
selective noradrenaline re-uptake
inhibitor with activity in rodent models of
pain and depression. Br J Pharmacol.
; 160 (5): 1105-1118.
. Van Orden LJ, Van Dyke PM, Saito DR,
Church TJ, Chang R, Smith JA, Martin
WJ, Jaw-Tsai S and Stangeland EL. A
novel class of 3-(phenoxy-phenylmethyl)-pyrrolidines as potent and
balanced norepinephrine and serotonin
reuptake inhibitors: synthesis and
structure-activity relationships. Bioorg
Med Chem Lett. 2013; 23 (5): 1456-
. Marks DM, Shah MJ, Patkar AA,
Masand PS, Park GY and Pae CU.
Serotonin-norepinephrine reuptake
inhibitors for pain control: premise and
promise. Curr Neuropharmacol. 2009; 7
(4): 331-336.
. Bannister K, Bee LA and Dickenson AH.
Preclinical and early clinical
investigations related to monoaminergic
pain modulation. Neurotherapeutics.
; 6 (4): 703-712.
. Mostert JP, Koch MW, Heerings M,
Heersema DJ and De Keyser J.
Therapeutic potential of fluoxetine in
neurological disorders. CNS Neurosci
Ther. 2008; 14 (2): 153-164.
. Tamiya J, Dyck B, Zhang M, Phan K,
Fleck BA, Aparicio A, Jovic F, Tran JA,
Vickers T, Grey J, Foster AC and Chen
C. Identification of 1S, 2R-milnacipran
analogs as potent norepinephrine and
serotonin transporter inhibitors.
Bioorganic & Medicinal Chemistry
Letters. 2008; 18 (11): 3328-3332.
. Chappell AS, Ossanna MJ, Liu-Seifert
H, Iyengar S, Skljarevski V, Li LC,
Bennett RM and Collins H. Duloxetine, a
centrally acting analgesic, in the
treatment of patients with osteoarthritis
knee pain: a 13-week, randomized,
placebo-controlled trial. Pain. 2009; 146
(3): 253-260.
. Collins SL, Moore RA, McQuayHj and
Wiffen P. Antidepressants and
anticonvulsants for diabetic neuropathy
and postherpetic neuralgia: a
quantitative systematic review. J Pain
Symptom Manage. 2000; 20 (6): 449-
. Solitar BM. Fibromyalgia: knowns,
unknowns, and current treatment. Bull
NYU Hosp Jt Dis. 2010; 68 (3): 157-161.
. Murty MSR, Solimabi and Kamat SY.
Isolation of 2-benzoxazolinone from
Acanthus ilicifolius. Indian J. Pharm. Sci.
; 46: 218-219.
. Sam J and Plampin JN. Benzoxazoles:
Potent Skeletal Muscle Relaxants. J
Pharm Sci. 1964; 53: 538-544.
. Goekhan N, Aktay G and Erdogan H.
Synthesis of some new pyridylethylated
benzoxa(thia)zolinones with analgesic
activity. Turk. J. Chem. 2004; 28: 123-
. Dogruer DS, Unlu S, Sahin MF and
Yesilada E. Anti-nociceptive and antiinflammatory activity of some (2-
benzoxazolone-3-yl and 2-
benzothiazolone-3-yl) acetic acid
derivatives. Farmaco. 1998; 53 (1): 80-
. Benson DA, Karsch-Mizrachi I, Lipman
DJ, Ostell J and Wheeler DL. GenBank.
Nucleic Acids Res. 2007; 35: D21-D25.
. Altschul SF, Madden TL, Schaffer AA,
Zhang J, Zhang Z, Miller W and Lipman
DJ. Gapped BLAST and PSI-BLAST: a
new generation of protein database
search programs. Nucleic Acids Res.
; 25 (17): 3389-3402.
. Sali A and Blundell TL. Comparative
protein modelling by satisfaction of
spatial restraints. J Mol Biol. 1993; 234
(3): 779-815.
. Wacker D, Wang C, Katritch V, Han
GW, Huang XP, Vardy E, McCorvy JD,
Jiang Y, Chu M, F. Y. Siu, W. Liu, H. E.
Xu, V. Cherezov, B. L. Roth and R. C.
Stevens. Structural features for
functional selectivity at serotonin
receptors. Science. 2013; 340 (6132):
-619.
. R. A. Laskowski, M. W. MacArthur, D. S.
Moss and J. M. Thornton. PROCHECK:
a program to check the stereochemical
quality of protein structures. J. Appl.
Crystallogr. 1993; 26: 283-291.
. Bolton EE, Wang Y, Thiessen PA and
Bryant SH. PubChem: Integrated
platform of small molecules and
biological activities. Annu. Rep. Comput.
Chem. 2008; 4: 217-241.
. Pettersen EF, Goddard TD, Huang CC,
Couch GS, Greenblatt DM, Meng EC
and Ferrin TE. UCSF Chimera--a
visualization system for exploratory
research and analysis. J Comput Chem.
; 25 (13): 1605-1612.
. Berman HM, Westbrook J, Feng Z,
Gilliland G, Bhat TN, Weissig H,
Shindyalov IN and Bourne PE. The
Protein Data Bank. Nucleic Acids Res.
; 28: 235-242.
. Morris GM, Goodsell DS, Halliday RS,
Huey R, Hart WE, Belew RK and Olson
AJ. Automated docking using a
Lamarckian genetic algorithm and an
empirical binding free energy function. J.
Comput. Chem. 1998; 19: 1639-1662.
. Seeliger D and de Groot BL. Ligand
docking and binding site analysis with
PyMOL and Autodock/Vina. J Comput
Aided Mol Des. 2010; 24 (5): 417-422.
. Morris GM, Huey R, Lindstrom W,
Sanner MF, Belew RK, Goodsell DS and
Olson AJ. AutoDock4 and
AutoDockTools4: Automated docking
with selective receptor flexibility. J
Comput Chem. 2009; 30 (16): 2785-
. Lill MA and Danielson ML. Computeraided drug design platform using
PyMOL. J Comput Aided Mol Des. 2011;
(1): 13-19.
